GPAT3 is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma
Yu Zhou, Huakan Zhao, Ran Ren, Mingyue Zhou, Jiangang Zhang, Zhijuan Wu, Yu Chen, Juan Lei, Yang Chen, Ying Yu, Yongsheng Li
Abstract
Our data demonstrate that GPAT3 elevation in HCC cells reprograms triglyceride metabolism which contributes to acquired resistance to sorafenib, which suggests GPAT3 as a potential target for enhancing the sensitivity of HCC to sorafenib.
Topics & Concepts
Hepatocellular carcinomaSorafenibCancer researchMedicineOncologyInternal medicineCancer, Lipids, and MetabolismPeroxisome Proliferator-Activated ReceptorsHepatocellular Carcinoma Treatment and Prognosis